Drug Patent Watch
JUNE 22, 2021
Annual Drug Patent Expirations for AIRDUO+RESPICLICK Airduo Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from three suppliers. There are twenty-one…. The post New patent expiration for Teva Pharm drug AIRDUO RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
JUNE 25, 2021
Ethicon*, part of the Johnson & Johnson Medical Devices Companies,**today announced the launch of the ENSEAL X1 Curved Jaw Tissue Sealer, a new advanced bipolar energy device that increases procedural efficiency [1] and provided stronger sealing [2] and better access to more tissue than LigaSure Maryland. [3] The device is indicated for colorectal, gynecological, bariatric surgery and thoracic procedures.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
JUNE 25, 2021
This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channels Update: 340B Controversies and Outlook. More than 2,000 people have already registered. Click here to see the original post and comments from April 2021. Time for Drug Channels ' annual update on pricing at six of the largest pharmaceutical manufacturers—Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, and Sanofi.
Drug Patent Watch
JUNE 22, 2021
Annual Drug Patent Expirations for ARMONAIR+RESPICLICK Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are nineteen…. The post New patent expiration for Teva Pharm drug ARMONAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Drug Patent Watch
JUNE 25, 2021
This chart shows the pharmaceutical companies with the most suspension dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most suspension dosed drugs…. The post Which pharmaceutical companies have the most suspension dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Patent Watch
JUNE 22, 2021
Annual Drug Patent Expirations for PROAIR+RESPICLICK Proair Respiclick is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from two suppliers. There are…. The post New patent expiration for Teva Branded drug PROAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 22, 2021
Annual Drug Patent Expirations for NOCDURNA Nocdurna is a drug marketed by Ferring Pharms Inc and is included in one NDA. It is available from one supplier. There are nine…. The post New patent for Ferring Pharms drug NOCDURNA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 23, 2021
This chart shows the pharmaceutical companies with the most patents in Slovakia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Slovakia? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 23, 2021
Annual Drug Patent Expirations for SOOLANTRA Soolantra is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from three suppliers. There are eleven…. The post New patent for Galderma Labs drug SOOLANTRA appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Patent Watch
JUNE 25, 2021
Annual Drug Patent Expirations for OXBRYTA Oxbryta is a drug marketed by Global Blood Theraps and is included in one NDA. There are eight patents protecting this drug. This drug…. The post New patent for Global Blood drug OXBRYTA appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
JUNE 25, 2021
CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced results of the second interim analysis of its international pivotal Phase 2b/3 study in approximatively 40,000 subjects (the HERALD study) of CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV.
The Pharma Data
JUNE 25, 2021
KEYNOTE-564 is the First Phase 3 Study to Show Positive Results for Adjuvant Immunotherapy in RCC. First-Time Disease-Free Survival Data to be Presented During Plenary Session at the 2021 ASCO Annual Meeting. KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the potential adjuvant treatment of patients
The Pharma Data
JUNE 25, 2021
Global Phase 3 TOPAZ-1 study will evaluate the efficacy and safety of BIIB059, as compared to placebo, in active systemic lupus erythematosus (SLE) , a debilitating autoimmune disease which has limited treatment options Positive Phase 2 LILAC study efficacy results support the further evaluation of BIIB059 in SLE. Biogen today announced that the first patient has been dosed in the global clinical study, TOPAZ-1.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
The Pharma Data
JUNE 25, 2021
Biogen Inc. (Nasdaq: BIIB) announced today that it will participate in SVB Leerink’s 3 rd Annual CNS Forum. The webcast will be live on Tuesday, June 29, at 1:50 p.m. ET. To access the live webcast, please go to the investors section of Biogen’s website at investors.biogen.com. An archived version of the webcast will be available following the presentation.
The Pharma Data
JUNE 25, 2021
Biogen (Nasdaq: BIIB) and Eisai Inc. , U.S. subsidiary of Eisai Co., Ltd. today issued the following statement: On June 7, 2021, ADUHELM (aducanumab-avwa) 100 mg/mL solution for injection was granted accelerated approval by the U.S. Food and Drug Administration (FDA). We are committed to responding to questions from the Alzheimer’s disease community and providing more details about our plans.
The Pharma Data
JUNE 25, 2021
AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. The trial did not meet the primary endpoint of post-exposure prevention of symptomatic COVID-19 with AZD7442 compared to placebo.
The Pharma Data
JUNE 24, 2021
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY ® , the companies’ COVID-19 vaccine, to the European Union (EU), with an option for the EC to request up to an additional 900 million doses. This press release features multimedia. View the full release here: [link].
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
The Pharma Data
JUNE 24, 2021
today announced that the first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine, currently authorized by the Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA).
The Pharma Data
JUNE 24, 2021
today announced that the Conditional Marketing Authorization (CMA) for COMIRNATY ® in the European Union (EU) has been expanded to include individuals 12 to 15 years of age. This follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize the vaccine in this age group. The extended indication for the CMA for COMIRNATY is valid in all 27 EU member states.
The Pharma Data
JUNE 24, 2021
today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC).
Drug Patent Watch
JUNE 24, 2021
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Italy. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Italy? appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
JUNE 24, 2021
Annual Drug Patent Expirations for LIVALO Livalo is a drug marketed by Kowa Co and is included in one NDA. It is available from one supplier. There are three patents…. The post New patent expiration for Kowa Co drug LIVALO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 23, 2021
Annual Drug Patent Expirations for ZEPOSIA Zeposia is a drug marketed by Celgene Intl and is included in one NDA. It is available from one supplier. There are three patents…. The post New patent for Celgene Intl drug ZEPOSIA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 22, 2021
This chart shows the pharmaceutical companies with the most patents in Lithuania. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Lithuania? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 22, 2021
Annual Drug Patent Expirations for AIRDUO+DIGIHALER Airduo Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from three suppliers. There are twenty-five…. The post New patent expiration for Teva Pharm drug AIRDUO DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 22, 2021
Annual Drug Patent Expirations for PROAIR+DIGIHALER Proair Digihaler is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from two suppliers. There are…. The post New patent expiration for Teva Branded drug PROAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
97 
Let's personalize your content